Dyadic International, Inc., a biotechnology company, engages in the discovery, development, production, and sale of enzymes and other proteins in the United States and the Netherlands. It utilizes its patented and proprietary C1 technology and other technologies to conduct research, development, and commercial production of human and animal vaccines, monoclonal antibodies, biosimilars and/or biobetters, and other therapeutic proteins. Dyadic International, Inc. has a research collaboration with Mitsubishi Tanabe Pharma Corporation to explore the potential of its C1 technology to produce two vital therapeutic proteins for human health indications.
Showcase to 300+ investors and pharma at our 5th flagship LSX World Congress.
Plus save £500 before 14th December!
LSX is an influential community of senior life science decision makers. We connect senior life science executives with access to the capital, intelligence, innovation, and partners they need to grow their businesses.